Clinically reviewed by Dr. Pipat Finn, M.D., Senior Doctor, Doctor Pattaya.
Last reviewed: October 2026
Mounjaro (tirzepatide) is a once-weekly injection that activates two hormones involved in blood sugar and appetite control: GLP-1 and GIP. In a head-to-head trial, it produced greater average weight loss than semaglutide. Treatment starts at 2.5 mg weekly and increases gradually over several months. A doctor consultation is required before starting.
You have done the research. You know what tirzepatide is, you have seen the numbers, and now you want to actually start rather than spend another week reading about it. Maybe you are a long-term expat in Pattaya who has watched the scales creep up and finally decided enough is enough. Maybe you are here for a few weeks and realised this is a practical window to get assessed, start a plan, and take that plan home. Either way, you want straight answers, not a lecture.
This guide covers how tirzepatide works, what the clinical trials showed, the full dosing schedule, who should not use it, how to handle side effects in Pattaya’s heat, and how to get started here. If you want a broader look at GLP-1 options first, our complete overview of Mounjaro and GLP-1 therapy is a good place to begin.

What Makes Tirzepatide Different from Other Weight Loss Injections
Most weight loss injections activate one receptor: GLP-1. That slows digestion, reduces appetite, and helps the pancreas release insulin after meals. Tirzepatide activates two: GLP-1 and GIP. GIP is a separate incretin hormone that also influences insulin release and fat metabolism.
In head-to-head trials, tirzepatide lowered blood sugar and body weight more than semaglutide, a GLP-1 only medicine. Some patients describe a quieting of constant food thoughts, sometimes called "food noise."
What the Clinical Trials Actually Showed
The SURPASS trial programme tested tirzepatide in people with type 2 diabetes. Across those trials, tirzepatide reduced HbA1c, your average blood sugar over roughly three months, more than comparator medications including semaglutide, insulin degludec, and insulin glargine.
The SURMOUNT-1 trial tested tirzepatide in people with obesity but without diabetes. At 5 mg, participants lost an average of around 15% of body weight over 72 weeks. At 15 mg, average loss reached around 20.9%. These are averages from a controlled trial. Your result depends on diet, activity, and how long you stay on treatment.
The 2.5 mg starting dose is meant to help your body adjust. It is not a long-term treatment dose. In a large heart trial in people with type 2 diabetes and heart disease, tirzepatide was at least as good as dulaglutide, another diabetes injection, at preventing heart attack, stroke, and heart-related death. Tirzepatide has also received regulatory approval for obstructive sleep apnea in people with obesity in some markets, which matters for expats managing more than one condition.
The Full Mounjaro Dosing Schedule
Tirzepatide is injected under the skin once a week. The dose increases gradually to let your body adjust and keep side effects manageable.
| Week | Dose |
|---|---|
| Weeks 1 to 4 | 2.5 mg once weekly |
| Weeks 5 to 8 | 5 mg once weekly |
| Weeks 9 to 12 | 7.5 mg once weekly |
| Weeks 13 to 16 | 10 mg once weekly |
| Weeks 17 to 20 | 12.5 mg once weekly |
| Week 21 onward | 15 mg once weekly (maximum dose) |
Not everyone needs to reach 15 mg. Some patients hit their target blood sugar or weight loss goal at a lower dose and stay there. Your doctor decides when or whether to increase, based on how you are responding and tolerating each step. Never increase your dose without medical review.
Who Should Not Take Mounjaro
A proper consultation matters precisely because of this section.
Tirzepatide is contraindicated if you or a close blood relative have had medullary thyroid carcinoma, a specific type of thyroid cancer. It is also contraindicated in Multiple Endocrine Neoplasia syndrome type 2. A similar warning appears on semaglutide and other long-acting GLP-1 medicines. It should also not be used if you have had a serious allergic reaction to tirzepatide.
Tirzepatide should not be used in type 1 diabetes and is not recommended in pregnancy. People with a history of pancreatitis need to discuss that with their doctor before starting. If you develop severe, persistent abdominal pain while on treatment, stop and seek care immediately. Also see a doctor quickly for a lump or swelling in your neck, trouble swallowing, pain in your upper right belly or yellow skin, signs of a severe allergic reaction, or very little urine from dehydration. If you use the contraceptive pill, ask about adding a barrier method after starting and after each dose increase, because tirzepatide can make the pill less reliable. Dose adjustments may be needed if you are also on insulin or insulin secretagogues, as that combination can increase the risk of low blood sugar.
How to Inject Mounjaro
The Mounjaro KwikPen is a pre-filled pen that holds four weekly doses. Before each injection you attach a new needle, prime the pen, and dial your dose. You then press the needle into cleaned skin on your abdomen, thigh, or upper arm, press and hold the button, and count slowly as the instructions show.
If you are starting treatment at Doctor Pattaya, we walk you through your first injection in the clinic. You leave knowing exactly how to do it yourself, and you have a number to call at any hour if something feels off. Our team is available around the clock, so help is never far away whether you are in South Pattaya, Pratumnak, or anywhere across the area.
Authentic vs Compounded Tirzepatide
This is worth paying close attention to in Thailand. Branded Mounjaro from Eli Lilly comes in a pre-filled KwikPen with a verified dose. It is stored under proper cold-chain conditions from manufacturer to clinic. What you inject is exactly what the label says.
Compounded tirzepatide, sold by peptide vendors and some online suppliers in Thailand, is a different product. It typically arrives as a powder vial that the patient mixes and measures themselves. There is no independent sterility guarantee, no regulatory oversight of the dose, and no cold-chain assurance. Some products are marketed for research use only, meaning not for human use. The risk from underdosing, contamination, or improper storage is real. At Doctor Pattaya we prescribe and supply branded Eli Lilly Mounjaro only.
Getting Started with Mounjaro in Pattaya
The process is straightforward. You come in for a consultation, we review your medical history, current medications, and any contraindications. If tirzepatide is appropriate for you, your first injection can happen in the clinic before you leave.
Unused pens should be kept in the fridge and away from heat. If you are staying near Jomtien Beach, Pratumnak Hill, or Naklua, a doctor hotel visit is available if getting to the clinic does not fit your schedule. Pattaya’s walk-in, 24/7 setup is a practical advantage that works well for people who want to start quickly and without a long wait.
Starting Mounjaro as a Tourist or Short-Stay Visitor
This is a fair question. You have two weeks in Pattaya. Can you start here and continue at home?
Yes, with planning. The consultation, first dose, and self-injection training all happen in one visit. Ask for a written summary of your starting dose and dose plan to take to your home-country doctor.
One honest note: tirzepatide is a long-term commitment. The SURMOUNT-1 results came at 72 weeks, not two. Starting treatment here is a genuine option, but only if you have a clear plan for where you will get your next pen and who will supervise your dose increases. A good doctor asks about that plan on day one. We do.
Managing Tirzepatide Side Effects in Pattaya
The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are most likely during dose increases and tend to ease as your body adjusts.
Nausea and vomiting cause fluid loss, and the tropical climate accelerates dehydration faster than you might expect at home. Drink water consistently, especially in the first couple of days after a dose increase. If you cannot keep fluids down, that is not a wait-and-see situation. Come in.
Alcohol compounds dehydration and irritates a digestive system that is already adjusting. Cutting back during the first month, particularly around injection days, may make the early phase easier. Large fatty meals, easy to land on after a beach dinner in Jomtien, are a common nausea trigger. Smaller, lower-fat meals work better during titration.
Time your weekly injection so it does not fall the day before a big event. Some people notice side effects most in the day or two after the injection.
If nausea is severe and oral fluids are not staying down, IV drip therapy is available at Doctor Pattaya around the clock to restore hydration quickly. Do not wait until you are significantly unwell before asking for help.
When Progress Stalls
Weight loss on tirzepatide is not a straight line. Many patients see early changes, then a plateau, sometimes for several weeks. This is normal and does not mean the treatment has stopped working.
Common reasons include the dose not yet being at your effective level, calorie intake creeping up as appetite suppression feels less dramatic over time, or the body settling at a new setpoint. A dose increase, reviewed and approved by your doctor, is sometimes the right next step. Sometimes the answer is dietary.
Do not increase your own dose without medical review. If you are managing your treatment remotely after leaving Pattaya, contact your home prescriber before making any changes. For any ongoing questions about GLP-1 therapy and what to expect during the full titration schedule, our Mounjaro and GLP-1 therapy page has more detail.
Mounjaro (tirzepatide) is available at Doctor Pattaya for tourists, expats, and residents. We offer walk-in consultations and in-clinic injection training. We are open 24 hours a day, seven days a week. Walk in or contact us to book.
Frequently Asked Questions
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021.
- U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing Information, 2026.
- American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide. Journal scan of Aronne LJ et al., NEJM, 2025.
- American College of Cardiology. SURPASS-CVOT: Is Tirzepatide Superior to Dulaglutide in Patients With T2D and ASCVD? Journal scan, 2026.
- Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine, 2026.
The information in this article is for educational purposes only and does not constitute medical advice. It should not be used to self-diagnose or replace a consultation with a qualified physician. If you have concerns about your health, contact a licensed medical professional. For appointments at Doctor Pattaya, visit doctorpattaya.com.


